BACKGROUND:Omega-3fatty acids reduced heart rate (HR) and blood pressure (BP) in some studies, but dose-response studies are rare, and little is known about underlying mechanisms. PURPOSE: We examined effects of 0.85 g/day eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) (low dose) and 3.4 g/day EPA + DHA (high dose) on HR and systemic hemodynamics during rest, speech, and foot cold pressor tasks. METHODS: This was a dose-response, placebo-controlled, double-blind, randomized, crossover trial (8-week treatment, 6-week washout) in 26 adults. RESULTS: Throughout the testing sessions, HR was reduced in a dose-dependent manner. The high dose reduced BP and stroke volume and increased pre-ejection period. Reductions in BP were associated with increases in erythrocyte omega-3 fatty acids. CONCLUSIONS:High-dose long-chain omega-3 fatty acids can reduce BP and HR, at rest and during stress. These findings suggest that at-risk populations may achieve benefits with increased omega-3 intake. The trial was registered on ClinicalTrials.gov (NCT00504309).
RCT Entities:
BACKGROUND:Omega-3 fatty acids reduced heart rate (HR) and blood pressure (BP) in some studies, but dose-response studies are rare, and little is known about underlying mechanisms. PURPOSE: We examined effects of 0.85 g/day eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) (low dose) and 3.4 g/day EPA + DHA (high dose) on HR and systemic hemodynamics during rest, speech, and foot cold pressor tasks. METHODS: This was a dose-response, placebo-controlled, double-blind, randomized, crossover trial (8-week treatment, 6-week washout) in 26 adults. RESULTS: Throughout the testing sessions, HR was reduced in a dose-dependent manner. The high dose reduced BP and stroke volume and increased pre-ejection period. Reductions in BP were associated with increases in erythrocyte omega-3 fatty acids. CONCLUSIONS: High-dose long-chain omega-3 fatty acids can reduce BP and HR, at rest and during stress. These findings suggest that at-risk populations may achieve benefits with increased omega-3 intake. The trial was registered on ClinicalTrials.gov (NCT00504309).
Authors: M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman Journal: Lancet Date: 1989-09-30 Impact factor: 79.321
Authors: S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler Journal: Lancet Date: 1990-03-31 Impact factor: 79.321
Authors: Melinda S Schaller; Greg J Zahner; Warren J Gasper; William S Harris; Michael S Conte; Nancy K Hills; S Marlene Grenon Journal: J Clin Lipidol Date: 2017-06-24 Impact factor: 4.766
Authors: Katherine A Sauder; Ann C Skulas-Ray; Tavis S Campbell; Jillian A Johnson; Penny M Kris-Etherton; Sheila G West Journal: Psychosom Med Date: 2013-04-16 Impact factor: 4.312
Authors: Peter J H Jones; Vijitha K Senanayake; Shuaihua Pu; David J A Jenkins; Philip W Connelly; Benoît Lamarche; Patrick Couture; Amélie Charest; Lisa Baril-Gravel; Sheila G West; Xiaoran Liu; Jennifer A Fleming; Cindy E McCrea; Penny M Kris-Etherton Journal: Am J Clin Nutr Date: 2014-05-14 Impact factor: 7.045
Authors: Emilio A Herrera; Jorge G Farías; Alejandro González-Candia; Stefania E Short; Catalina Carrasco-Pozo; Rodrigo L Castillo Journal: Mar Drugs Date: 2015-02-04 Impact factor: 5.118
Authors: Mark G Filipovic; Stefanie Aeschbacher; Martin F Reiner; Simona Stivala; Sara Gobbato; Nicole Bonetti; Martin Risch; Lorenz Risch; Giovanni G Camici; Thomas F Luescher; Clemens von Schacky; David Conen; Juerg H Beer Journal: J Hypertens Date: 2018-07 Impact factor: 4.844